Rodzinak received his Bachelor of Science in chemistry and biology from Misericordia University, Dallas, Pennsylvania. He joined Southern Research in May 2016 and is currently a research chemist in the Chemistry Department. Prior to joining Southern Research, Rodzinak was employed by noted companies such as Merck Research Laboratories and DuPont/Merck Research Laboratories. At these organizations, he contributed to the identification and lead optimization space in a variety of therapeutic areas and drug target classes. With over 18 years of experience in drug discovery from various projects at these pharmaceutical companies, he continues to design and synthesize molecules in various therapeutic areas with a current focus on antivirals and anti-HIV therapeutics. Rodzinak was a key contributor in the NMDA, PDE9, PDE10, and mGluR2 therapeutic areas. He was instrumental in the discovery and design of MK-2206 for the treatment of cancer, which is currently in Phase II of clinical trials. He is also an inventor on 13 patents and has published three peer-reviewed manuscripts describing his work of novel chemical compounds.